We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

16 hedge funds and large institutions have $43.5M invested in Viridian Therapeutics in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

15,047% more capital invested

Capital invested by funds: $287K → $43.5M (+$43.2M)

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

100% more funds holding

Funds holding: 8 → 16 (+8)

1.09% more ownership

Funds ownership: 0% → 1.09% (+1.1%)

Holders
16
Holders Change
+8
Holders Change %
+100%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$35.9M
2
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
+$1.21M
3
Millennium Management
Millennium Management
New York
+$750K
4
Goldman Sachs
Goldman Sachs
New York
+$746K
5
DY
Dowling & Yahnke
California
+$460K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$53K
2
Deutsche Bank
Deutsche Bank
Germany
-$5K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$38.9M +$35.9M +208,326 New
UOTTAIMCU
2
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$1.31M +$1.21M +7,031 New
Millennium Management
3
Millennium Management
New York
$811K +$750K +4,347 New
Goldman Sachs
4
Goldman Sachs
New York
$807K +$746K +4,323 New
DY
5
Dowling & Yahnke
California
$498K +$460K +2,666 New
HighTower Advisors
6
HighTower Advisors
Illinois
$471K +$74.3K +431 +21%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$177K +$163K +946 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$148K +$137K +797 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$130K – – –
SCM
10
Segantii Capital Management
Hong Kong
$77K +$71.6K +415 New
Morgan Stanley
11
Morgan Stanley
New York
$66K +$61K +354 New
PCM
12
Prelude Capital Management
New York
$64K +$30.5K +177 +106%
Barclays
13
Barclays
United Kingdom
$25K +$23.3K +135 New
Creative Planning
14
Creative Planning
Kansas
$8K – – –
PAM
15
Panagora Asset Management
Massachusetts
$4K +$3.62K +21 New
BlackRock
16
BlackRock
New York
$1K +$1.38K +8 New
Renaissance Technologies
17
Renaissance Technologies
New York
– -$53K -706 Closed
Deutsche Bank
18
Deutsche Bank
Germany
– -$5K -71 Closed
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
– -$1K -15 Closed

VRDN Hedge Fund Activity: Q1 2017 in Review

16 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2017, worth a combined $43.5M — up 15,047% from $287K a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new VRDN positions and 3 closed out — a net gain of 9 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $35.9M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $53K sold.

  • 16 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2017, up from 8 in Q4 2016.
  • Funds reported $43.5M of Viridian Therapeutics stock for Q1 2017, up 15,047% quarter-over-quarter.
  • 12 funds opened new Viridian Therapeutics positions in Q1 2017 and 3 closed out, a net change of +9 holders.
  • The largest Viridian Therapeutics buyer in Q1 2017 was Fidelity Investments, an estimated $35.9M added.
  • The largest Viridian Therapeutics seller in Q1 2017 was Renaissance Technologies, an estimated $53K sold.

Based on aggregated 13F filings for Q1 2017.